Biologic Therapies III
Vasculitis and Biologics -
A Continuing Conundrum:
A Case-Based Approach
Release Date: April 21, 2010
Expiration Date: April 21, 2012
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Estimated Time of Completion: 15 minutes
Description
The Biologics Therapies Summit III Mini-Symposium Master Clinician Panel was captured and repurposed into a case-based format to discuss management strategies for clinicians caring for patients with rheumatic and inflammatory diseases. The cases include autoimmune and inflammatory disorders, common and rare infections associated with biologics, newer agents, and biologic use with existing conditions such as cancer and liver disease.
Objectives
At the conclusion of this activity, the participant will be able to do the following:
- Recognize the role of biologic therapy in the treatment of Wegener’s granulomatosis.
Target Audience
This case-based series is directed toward rheumatologists, gastroenterologists, dermatologists, pulmonologists, internal medicine physicians, nurse practitioners, physician assistants, and other health care professionals interested in or using biologic therapeutics in autoimmune and inflammatory disorders.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman, Department of Rheumatic & Immunologic Diseases
R.J. Fasenmeyer Chair of Clinical Immunology
Orthopaedic & Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Eamonn S. Molloy, MD, MS
Department of Rheumatic & Immunologic Diseases
Orthopaedic & Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty member has indicated that he may have a relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:
| Leonard H. Calabrese, DO | ||
| Consulting | Elan; Roche | |
| Consulting, Teaching & Speaking | Abbott; Amgen; Centocor; Genentech; Wyeth | |
The following faculty member has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:
Eamonn S. Molloy, MD, MS
The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:
Abbott Laboratories, Inc.
Amgen
Centocor Ortho Biotech
Genentech and Biogen Idec
Roche Laboratories, Inc.
UCB, Inc.
Wyeth
This CME activity was produced by The Cleveland Clinic Foundation R.J. Fasenmeyer Center for
Clinical Immunology and the Center for Continuing Education.
